Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other financing activities (2023 - 2025)

Kura Oncology (KURA) has disclosed Other financing activities for 3 consecutive years, with $515000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Other financing activities fell 83.06% to $515000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $3.7 million, a 39.98% decrease, with the full-year FY2025 number at $1.8 million, down 79.16% from a year prior.
  • Other financing activities was $515000.0 for Q2 2025 at Kura Oncology, up from $143000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $3.0 million in Q2 2024 to a low of $84000.0 in Q3 2023.
  • A 3-year average of $1.2 million and a median of $661000.0 in 2024 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: skyrocketed 2521.43% in 2024, then tumbled 94.4% in 2025.
  • Kura Oncology's Other financing activities stood at $84000.0 in 2023, then skyrocketed by 860.71% to $807000.0 in 2024, then crashed by 36.18% to $515000.0 in 2025.
  • Per Business Quant, the three most recent readings for KURA's Other financing activities are $515000.0 (Q2 2025), $143000.0 (Q1 2025), and $807000.0 (Q4 2024).